Innate Pharma (IPHA) Cash from Financing Activities (2019 - 2024)
Innate Pharma (IPHA) reported Cash from Financing Activities of -$6.4 million for Q4 2024, down 203.51% on a YoY basis from $6.2 million in Q1 2024, and down 203.51% quarter-over-quarter from -$2.1 million in Q4 2023.
Innate Pharma (IPHA) Cash from Financing Activities (2019 - 2024) Analysis & Trends
Innate Pharma has reported Cash from Financing Activities for 6 years, with the latest figure at -$6.4 million in Q4 2024.
- For the quarter ending Q4 2024, Cash from Financing Activities fell 203.51% year-over-year to -$6.4 million; the trailing twelve-month figure through Dec 2024 stood at -$9.9 million (down 55.5% YoY), and the FY2025 full-year result was $7.1 million, up 210.06% from the prior year.
- Cash from Financing Activities for Q4 2024 stood at -$6.4 million, down from -$2.1 million in the prior quarter.
- The five-year high for Cash from Financing Activities was -$1.0 million in Q2 2022, with the low at -$6.4 million in Q4 2024.
- Historically, Cash from Financing Activities has averaged -$2.1 million across 5 years, with a median of -$1.4 million in 2020.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities surged 30.62% — and 2024, when it sank 203.51%.
- Innate Pharma's Cash from Financing Activities stood at -$1.4 million in 2020, then declined by 5.21% to -$1.5 million in 2021, then retreated by 26.32% to -$1.9 million in 2022, then fell by 13.42% to -$2.1 million in 2023, then slumped by 203.51% to -$6.4 million in 2024.
- The last three Cash from Financing Activities figures came in at -$6.4 million (Q4 2024), -$2.1 million (Q4 2023), and -$1.4 million (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 85,464.43 |
| 10 | Innate Pharma | 194.19 Mn | 194.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -6.42 Mn |
| Dec 31, 2024 | -6.42 Mn |
| Dec 31, 2023 | -2.12 Mn |
| Dec 31, 2023 | -2.12 Mn |
| Jun 30, 2023 | -1.36 Mn |
| Jun 30, 2023 | -1.36 Mn |
| Dec 31, 2022 | -1.87 Mn |
| Dec 31, 2022 | -1.87 Mn |
| Jun 30, 2022 | -1.02 Mn |
| Jun 30, 2022 | -1.02 Mn |
| Jun 30, 2021 | -1.48 Mn |
| Jun 30, 2021 | -1.48 Mn |
| Dec 31, 2020 | -1.40 Mn |
| Dec 31, 2020 | -1.40 Mn |
| Jun 30, 2020 | -1.32 Mn |
| Jun 30, 2020 | -1.32 Mn |
| Jun 30, 2019 | -867,449.38 |
| Jun 30, 2019 | -867,449.38 |